Annovis Initiates Key Studies in 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 16 2026
0mins
Should l Buy ANVS?
"The year 2025 was a landmark period for Annovis, one in which we took decisive steps toward bringing buntanetap to patients," said Maria Maccecchini, Ph.D., Founder and CEO of Annovis. "We initiated our pivotal Phase 3 AD study and later launched an OLE PD study, both critical milestones on the path to an NDA submission. Throughout the year, we remained focused on designing, preparing, and executing these studies with the highest standards of rigor while maintaining our scientific presence through key conferences, meetings, and publications. Equally important, we also revealed new biomarker data on buntanetap from our ongoing analysis of the completed studies, reinforcing the drug's therapeutic potential."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ANVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ANVS
Wall Street analysts forecast ANVS stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.150
Low
8.00
Averages
12.50
High
17.00
Current: 2.150
Low
8.00
Averages
12.50
High
17.00
About ANVS
Annovis Bio, Inc. is a late-stage clinical drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), and Parkinson’s disease (PD). The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NeuroRPM Partners with Annovis for Parkinson's Disease Monitoring
- Clinical Trial Collaboration: NeuroRPM's FDA-cleared wearable platform will be utilized in Annovis Bio's ANVS-25002 Parkinson's disease clinical trial, expected to enroll around 500 patients, aiming to enhance treatment outcomes through real-time monitoring.
- Data Collection Innovation: The platform leverages the Apple Watch to passively collect movement data, providing continuous measurement of key Parkinson's motor symptoms, thereby assisting researchers in more accurately assessing treatment responses.
- AI Technology Application: NeuroRPM's AI-enabled monitoring device analyzes complex symptom patterns, enhancing understanding of symptom fluctuations in patients' daily lives, thus providing a richer evidence base for clinical research.
- Long-term Monitoring Commitment: Following the trial, participants may continue using NeuroRPM for ongoing clinical monitoring, indicating the platform's long-term application potential in Parkinson's disease management, helping patients achieve better treatment experiences.
See More
Annovis Biopress Reports FY GAAP EPS of -$1.40
- Earnings Report: Annovis Biopress reported a FY GAAP EPS of -$1.40, indicating challenges in profitability that may affect investor confidence and market perception.
- Cash Position: As of December 31, 2025, Annovis had cash and cash equivalents totaling $19.5 million, a significant increase from $10.6 million in 2024, suggesting improved financial management.
- Funding Outlook: The company estimates that its current cash and equivalents, including proceeds from stock offerings in Q4 2025, will fund operations into Q3 2026, indicating a degree of financial stability.
- Share Count: Annovis had 27.2 million shares of common stock outstanding as of December 31, 2025, reflecting the company's activity in the capital markets and the stability of its shareholder structure.
See More
Healthcare Stocks with Strong Earnings Momentum Earn A+ EPS Revision Grades
- Investor Attention: As the earnings season unfolds, mid to low market capitalization healthcare stocks are drawing investor attention due to their strong earnings momentum, indicating growing market confidence in this sector.
- Analyst Expectations: The EPS Revision Grade reflects the trend in analyst earnings estimates, with A+ ratings indicating optimistic projections for future performance, potentially driving stock prices higher.
- List of A+ Rated Stocks: Currently, companies such as Aldeyra Therapeutics, Altimmune, Annovis Bio, and Assertio Holdings have received A+ EPS Revision Grades, showcasing their strong performance in the eyes of analysts.
- Market Strategy Impact: These A+ rated healthcare stocks are likely to attract more investor interest, potentially triggering positive sentiment towards the healthcare sector as a whole, thereby enhancing the performance of related ETFs.
See More
Annovis to Conduct 36-Month Extension Study for Further Assessment of Buntanetap in Parkinson's Disease
Long-term Study Launch: Annovis Bio, Inc. is set to begin a long-term open-label extension study in January 2026 to evaluate the effects of Buntanetap on Parkinson's disease patients over three years, aiming to enroll 500 participants across multiple U.S. sites.
Cohorts and Objectives: The study will include two cohorts: former participants from earlier studies and patients receiving deep brain stimulation, focusing on the long-term safety, efficacy, and potential disease-modifying properties of Buntanetap.
Regulatory Preparation: This extension study is part of Annovis' strategy to support a future New Drug Application, as it aims to meet FDA requirements for total patient numbers and treatment duration, building on previous studies involving over 1,200 patients.
Market Performance: Annovis' stock has fluctuated between $1.11 and $5.60 over the past year, closing at $3.67 and rising to $3.79 in overnight trading, reflecting investor interest in the company's developments in Parkinson's disease treatment.
See More
Annovis Initiates 36-Month Study for Parkinson's Drug Buntanetap
- Study Launch: Annovis Bio announced the initiation of a 36-month Open-Label Extension study starting January 2026, aiming to enroll 500 Parkinson's patients to evaluate the long-term safety and efficacy of the drug buntanetap, thereby providing continued treatment access for patients.
- Patient Populations: The study will include former clinical trial participants and patients receiving deep brain stimulation, aiming to assess the effects of buntanetap in different treatment contexts, addressing a significant gap in clinical research for underserved populations.
- Biomarker Collection: Throughout the study, skin and plasma biomarkers will be collected to deepen the understanding of disease progression and treatment effects, aiding the company in comprehending buntanetap's potential as a disease-modifying therapy.
- NDA Readiness: This study will assist Annovis in meeting FDA patient exposure requirements, with total patient participation expected to reach approximately 1,500, ensuring the company is well-prepared for future New Drug Application submissions.
See More
Annovis Bio to Host Webinar on Clinical Progress and Future Directions
- Webinar Announcement: Annovis Bio will host a corporate update webinar on January 28, 2026, featuring CEO Maria Maccecchini, who will discuss recent progress and ongoing clinical programs, likely attracting significant interest from investors and patients.
- Clinical Progress Momentum: The company has made notable advancements in treating neurodegenerative diseases, driving strong market momentum, with additional milestones expected in early 2026, which will further bolster investor confidence.
- Interactive Engagement Opportunity: The webinar will include a live Q&A session, encouraging participants to submit questions in advance, aimed at enhancing direct dialogue with the community and increasing transparency and trust.
- Mission Reaffirmation: Annovis Bio is dedicated to developing innovative therapies that improve the quality of life for patients with Alzheimer's and Parkinson's diseases, underscoring its long-term commitment in the neurodegeneration space.
See More
NeuroRPM Partners with Annovis for Parkinson's Disease Monitoring
- Clinical Trial Collaboration: NeuroRPM's FDA-cleared wearable platform will be utilized in Annovis Bio's ANVS-25002 Parkinson's disease clinical trial, expected to enroll around 500 patients, aiming to enhance treatment outcomes through real-time monitoring.
- Data Collection Innovation: The platform leverages the Apple Watch to passively collect movement data, providing continuous measurement of key Parkinson's motor symptoms, thereby assisting researchers in more accurately assessing treatment responses.
- AI Technology Application: NeuroRPM's AI-enabled monitoring device analyzes complex symptom patterns, enhancing understanding of symptom fluctuations in patients' daily lives, thus providing a richer evidence base for clinical research.
- Long-term Monitoring Commitment: Following the trial, participants may continue using NeuroRPM for ongoing clinical monitoring, indicating the platform's long-term application potential in Parkinson's disease management, helping patients achieve better treatment experiences.
See More
Annovis Biopress Reports FY GAAP EPS of -$1.40
- Earnings Report: Annovis Biopress reported a FY GAAP EPS of -$1.40, indicating challenges in profitability that may affect investor confidence and market perception.
- Cash Position: As of December 31, 2025, Annovis had cash and cash equivalents totaling $19.5 million, a significant increase from $10.6 million in 2024, suggesting improved financial management.
- Funding Outlook: The company estimates that its current cash and equivalents, including proceeds from stock offerings in Q4 2025, will fund operations into Q3 2026, indicating a degree of financial stability.
- Share Count: Annovis had 27.2 million shares of common stock outstanding as of December 31, 2025, reflecting the company's activity in the capital markets and the stability of its shareholder structure.
See More
Healthcare Stocks with Strong Earnings Momentum Earn A+ EPS Revision Grades
- Investor Attention: As the earnings season unfolds, mid to low market capitalization healthcare stocks are drawing investor attention due to their strong earnings momentum, indicating growing market confidence in this sector.
- Analyst Expectations: The EPS Revision Grade reflects the trend in analyst earnings estimates, with A+ ratings indicating optimistic projections for future performance, potentially driving stock prices higher.
- List of A+ Rated Stocks: Currently, companies such as Aldeyra Therapeutics, Altimmune, Annovis Bio, and Assertio Holdings have received A+ EPS Revision Grades, showcasing their strong performance in the eyes of analysts.
- Market Strategy Impact: These A+ rated healthcare stocks are likely to attract more investor interest, potentially triggering positive sentiment towards the healthcare sector as a whole, thereby enhancing the performance of related ETFs.
See More
Annovis to Conduct 36-Month Extension Study for Further Assessment of Buntanetap in Parkinson's Disease
Long-term Study Launch: Annovis Bio, Inc. is set to begin a long-term open-label extension study in January 2026 to evaluate the effects of Buntanetap on Parkinson's disease patients over three years, aiming to enroll 500 participants across multiple U.S. sites.
Cohorts and Objectives: The study will include two cohorts: former participants from earlier studies and patients receiving deep brain stimulation, focusing on the long-term safety, efficacy, and potential disease-modifying properties of Buntanetap.
Regulatory Preparation: This extension study is part of Annovis' strategy to support a future New Drug Application, as it aims to meet FDA requirements for total patient numbers and treatment duration, building on previous studies involving over 1,200 patients.
Market Performance: Annovis' stock has fluctuated between $1.11 and $5.60 over the past year, closing at $3.67 and rising to $3.79 in overnight trading, reflecting investor interest in the company's developments in Parkinson's disease treatment.
See More
Annovis Initiates 36-Month Study for Parkinson's Drug Buntanetap
- Study Launch: Annovis Bio announced the initiation of a 36-month Open-Label Extension study starting January 2026, aiming to enroll 500 Parkinson's patients to evaluate the long-term safety and efficacy of the drug buntanetap, thereby providing continued treatment access for patients.
- Patient Populations: The study will include former clinical trial participants and patients receiving deep brain stimulation, aiming to assess the effects of buntanetap in different treatment contexts, addressing a significant gap in clinical research for underserved populations.
- Biomarker Collection: Throughout the study, skin and plasma biomarkers will be collected to deepen the understanding of disease progression and treatment effects, aiding the company in comprehending buntanetap's potential as a disease-modifying therapy.
- NDA Readiness: This study will assist Annovis in meeting FDA patient exposure requirements, with total patient participation expected to reach approximately 1,500, ensuring the company is well-prepared for future New Drug Application submissions.
See More
Annovis Bio to Host Webinar on Clinical Progress and Future Directions
- Webinar Announcement: Annovis Bio will host a corporate update webinar on January 28, 2026, featuring CEO Maria Maccecchini, who will discuss recent progress and ongoing clinical programs, likely attracting significant interest from investors and patients.
- Clinical Progress Momentum: The company has made notable advancements in treating neurodegenerative diseases, driving strong market momentum, with additional milestones expected in early 2026, which will further bolster investor confidence.
- Interactive Engagement Opportunity: The webinar will include a live Q&A session, encouraging participants to submit questions in advance, aimed at enhancing direct dialogue with the community and increasing transparency and trust.
- Mission Reaffirmation: Annovis Bio is dedicated to developing innovative therapies that improve the quality of life for patients with Alzheimer's and Parkinson's diseases, underscoring its long-term commitment in the neurodegeneration space.
See More
